France: The French Act N°2011-2012 Dated 29 December 2011 Relating To The Reinforcement Of Health Security Of Medicinal And Health Products

This Act is focused on three main objectives:

  • Combating conflicts of interest and promoting transparency
  • Strengthening the monitoring of medicinal products and medical devices
  • Making better information more readily available to patients and healthcare professionals and, in particular, establishing binding provisions covering the advertisement of drugs, medical and diagnostics devices

This Act appears to be the French version of "Sunshine Acts" found in other countries. The Act also creates a new national agency, the Agence Nationale de Sécurité des Médicaments (ANSM), replacing the AFSSAPS in August of 2012. The ANSM will have new roles and powers, such as the power to impose administrative and financial penalties. Numerous provisions of this Act are still subject to follow-up decrees by the ANSM.

The main features of this new Act are the following:


  • Obligation to Declare Positions of Interest
    The Act expands the list of persons holding regulatory powers devolved to them by the French Ministry of Health, cabinet members and members of the new ANSM subject to the obligation to declare their interests when they take office: experts and all other professionals holding a regulatory role (New Article L.1451-1 of the French Public Health Code).
  • Administrative and Financial Penalties: Annulment of the decisions taken by these persons / Fines of up to 30,000 Euros. (New Article L.1454-2 of the French Public Health Code)
  • Obligation to Disclose Compensation
    The Act imposes an obligation to publicly disclose any agreement for providing direct or indirect compensation1 to a number of persons expressly listed (e.g. health professionals, organisations of health professionals, students and students associations of students in healthcare related studies, organisations of consumers of the health industry, health establishments, foundations, consulting organisations involved healthcare business, communication and publishing businesses involved in the life sciences market, software companies providing software concerning the drafting and delivery of medical prescriptions, companies involved in the education of healthcare professionals). (New Article L.1453-1 of the French Public Health Code)

    • Business Subject to the New Act: Business which manufacture, distribute and market cosmetics or medicinal products intended for humans, or which provide services linked with these products.
    • Financial Penalties Under the New Act: Up to 45,000 Euros fines for individuals and up to 225,000 Euros for companies, without affecting other possible additional penalties and sentences. (New Articles L.1454-3 seq. of the French Public Health Code)


  • The Act creates a new agency named Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM) replacing the AFSSAPS (New Articles L.5311-1 seq. of the French Public Health Code)

    • The ANSM will determine the risks and benefits linked to the use of health products intended for humans as well as cosmetics, monitoring the benefit/risk ratio of products and to act as an authoritative body with the power to impose fines and injunctions depending on the seriousness of the breach or violation.
    • The ANSM will publish all communications, notices, minutes and reports of commissions, committees and expert meetings within this agency (except in cases of industrial, commercial and professional confidentiality)

  • The Act also reinforces the obligations of pharmacovigilance in the medical industry with respect to the follow-up of their products after marketing authorisation (AMM)
    (The ANSM must be informed without delay of any imposed prohibition or restriction of any suspension of marketing of the authorisation-holder in France) – (New Articles L. 5121-9-2 seq. of the French Public Health Code)


  • A public web site with information on medications is to be set up.
  • Information campaigns on medication including its characteristics, risks and its proper use are to be conducted.
  • Continuing education obligations are imposed on all healthcare practitioners.
  • New provisions concerning the advertising of medicinal products

    • For medicinal products intended for humans

      • Advertising medicinal products is prohibited when the product is subject to a re-appraisal of its benefit/risk ratio following a reporting of pharmacoviligance (new Article L.5122-3 of the French Public Health Code)
      • Advertising campaigns concerning medicinal products intended to prevent smoking, reduce the addiction to smoking, or for vaccinations which are subject to medical prescription or reimbursed by French social security.
      • Advertising intended to healthcare professionals is subject to the mandatory prior authorisation of the ANSM. Such authorisation is referred to as « visa de publicité » (advertising visa) (new Article L.5122.9 of the French Public Health Code). Advertisements which have been published before the enactment of this reform shall remain subject to the old regime for one year following the date of this enactment (30 December 2011).

        • Amending the French Intellectual Property Code that now provides that documents needed for the granting of the visa de publicité shall not amount to counterfeiting.
      • Two year experimentation of a new system according to which medical representative shall only be able to make presentation and visits in healthcare establishments before a group of healthcare professionals (i.e. not on an individual basis).
    • Concerning medical devices: New Articles L.5211-3 seq. and L 5223-1 of the French Public Health Code

      • Control of advertising in relation to medical devices and harmonizing this regime to the regime applicable to medicinal products
      • Public advertising of reimbursed medical devices by the French NHS/Medicare is prohibited, except for devices which present a low risk to public health (list to be determined by decree).
      • Mandatory prior authorisation of the ANSM for medical devices presenting an important health risk (list to be determined by decree).

        • Penalties: a maximum of two years of imprisonment and a fine of up to 30,000 Euros in the following cases:

          • Where an advertisement is of a deceptive nature or presents a public health risk.
          • Where an advertisement is broadcasted or communicated without having obtained the visa de publicite, or if this authorisation was terminated or refused.

Other penalties are also provided for both individuals and legal entities.


The Act includes an important provision allowing a generic drug to copy the appearance or the texture of an original medicinal product in its oral shape (New Article L.5121-10-3 of the French Public Health Code).

* * * * * * * * * *

This Act will lead to noticeable changes for pharmaceutical and cosmetics companies (concerning transparency requirements) in France in the management of their internal procedures and their compliance requirements.


1. The threshold of which will be determined by decree.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions